Preferred Label : leukemia, mast-cell;
MeSH definition : A form of systemic mastocytosis (MASTOCYTOSIS, SYSTEMIC) characterized by the presence
of large numbers of tissue MAST CELLS in the peripheral blood without skin lesions.
It is a high-grade LEUKEMIA disease with bone marrow smear of 20% MAST CELLS, multi-organ
failure and a short survival.;
MeSH synonym : leukemias, mast-cell; mast cell leukemia; mast-cell leukemias; mast-cell leukemia; leukemia, mast cell;
Wikipedia link : https://en.wikipedia.org/wiki/Mast cell leukemia;
Origin ID : D007946;
UMLS CUI : C0023461;
Allowable qualifiers
Automatic exact mappings (from CISMeF team)
Currated CISMeF NLP mapping
DO Cross reference
False automatic mappings
Manual NTBT mappings (CISMeF)
ORDO relation(s)
Record concept(s)
Semantic type(s)
UMLS correspondences (same concept)
A form of systemic mastocytosis (MASTOCYTOSIS, SYSTEMIC) characterized by the presence
of large numbers of tissue MAST CELLS in the peripheral blood without skin lesions.
It is a high-grade LEUKEMIA disease with bone marrow smear of 20% MAST CELLS, multi-organ
failure and a short survival.
https://www.has-sante.fr/jcms/p_3359432/fr/ayvakyt-avapritinib-mastocytose-systemique-agressive-asm
https://www.has-sante.fr/jcms/p_3359458/fr/decision-n2022-0278/dc/sem-du-21-juillet-2022-du-college-de-la-haute-autorite-de-sante-portant-autorisation-d-acces-precoce-de-la-specialite-ayvakyt
2022
false
false
false
France
adult
Systemic Mastocytosis with an Associated Myeloid Neoplasm
protein kinase inhibitors
avapritinib
leukemia, mast-cell
treatment outcome
insurance, health, reimbursement
guidelines for drug use
continuity of patient care
administration, oral
evaluation of the transparency committee
avapritinib
aggressive systemic mastocytosis
mastocytosis, systemic
---
http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=FR&Expert=98851
https://www.orpha.net/data/patho/Pro/fr/Urgences_Mastocytose-frPro13309.pdf
2013
France
French
leukemia, mast-cell
emergency treatment
practice guideline
leukemia, mast-cell
---